The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...

Medicus Pharma (MDCX) announced feedback from Type C meeting with United States Food and Drug Administration. The purpose of the Type C meeting ...

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively ...

Study results suggest that “clinicians may be unaware of important clinical trial limitations identified by the FDA when making prescribing decisions,” researchers wrote.

Harmony Biosciences said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down more than 8%.

Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — ...

Medical journals and National Comprehensive Cancer Network guidelines rarely publish FDA-identified uncertainties about new ...

A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

Cecilia Bahit, MD, and Carolyn Lam, MBBS, PhD, FACC, discuss the barriers patients face when seeking access to clinical trial enrollment.

An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, ...

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer. Real-world studies represent an important step in the ...

A new Fred Hutch study surprisingly finds that many drugs initially written off as ineffective on cultured cancer cell lines ...